GLIS3 and tuberculosis: INH, a known anti-TB drug, targets several genes, namely, KATG, NDH, MSH, and NAT, but the primary target with dominant phenotype remains INHA, which encodes enoyl-Acyl-Carrier-Protein (ACP) termed as inhA reductase.